MYRTLE BEACH, S.C., Jan. 8, 2008 (PRIME NEWSWIRE) -- Emergent Health Corp. (Pink Sheets:EMGN) today announced that it has begun trading on the electronic quotation and trading system for OTC. Emergent is introducing Vita-Stim Life Enhancement to the public in limited quantities for beta testing. Vita-Stim is a patent pending product containing botanicals believed capable of mobilizing adult stem cells from a person's own bone marrow. Vita-Stim is the first in a series of products to be offered by Emergent to help people better their lives. Vita-Stim is what many believe is a new classification of nutritional supplementation that could some day approach one billion dollars. Emergent expects to expand its shareholder base, product availability as well as its product line in 2008.
Emergent is also currently beta testing two websites, Corporate: http://www.emergenthealth.com as well as a product test of Vita-Stim Life Enhancement: http://www.vita-stim.com
Emergent engages in the discovery, development and marketing of products designed to better mankind. Emergent believes it is positioning itself as a leader in the field of Regenerative Medicine defined by the National Institute of Health using nutritionally designed products. Intended products are to be marketed under third party label exemptions. Emergent is focusing current efforts on marketing licensed patent pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Emergent is also licensed under a patent pending application to market a dual acting all natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets. Research and Development is exploring other areas such as Secretogues that can naturally enhance a person's own Growth Hormone production and similar all natural bioactive formulations to enhance human performance safely, ethically, legally and utilizing known body mechanisms without the use of drugs. Emergent does not claim any of its products diagnose, treat, cure or prevent any disease. Emergent was founded in 2006 and headquartered in Myrtle Beach, SC.
This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.
This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.